iBio, Inc. Submits Matters to Security Holders

Ticker: IBIO · Form: 8-K · Filed: 2025-11-21T00:00:00.000Z

Sentiment: neutral

Topics: shareholder-vote, corporate-governance

TL;DR

iBio shareholders voted on something important, details to follow.

AI Summary

On November 20, 2025, iBio, Inc. filed an 8-K report to announce that it submitted matters to a vote of its security holders. The filing does not specify the nature of the matters or the outcome of the vote.

Why It Matters

This filing indicates that iBio, Inc. is engaging its shareholders on important corporate decisions, which could impact the company's future direction and shareholder value.

Risk Assessment

Risk Level: medium — The filing is a procedural update regarding a shareholder vote, but the lack of detail on the matters voted upon introduces uncertainty.

Key Players & Entities

FAQ

What specific matters were submitted for a vote by iBio, Inc. security holders?

The filing does not specify the exact matters that were submitted for a vote by iBio, Inc. security holders.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing was on November 20, 2025.

What is the state of incorporation for iBio, Inc.?

iBio, Inc. is incorporated in Delaware.

Where are iBio, Inc.'s principal executive offices located?

iBio, Inc.'s principal executive offices are located at 11750 Sorrento Valley Road, Suite 200, San Diego, California.

What is the purpose of this 8-K filing?

The purpose of this 8-K filing is to report the submission of matters to a vote of security holders by iBio, Inc.

From the Filing

0001104659-25-114800.txt : 20251121 0001104659-25-114800.hdr.sgml : 20251121 20251121080917 ACCESSION NUMBER: 0001104659-25-114800 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20251120 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20251121 DATE AS OF CHANGE: 20251121 FILER: COMPANY DATA: COMPANY CONFORMED NAME: iBio, Inc. CENTRAL INDEX KEY: 0001420720 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 262797813 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35023 FILM NUMBER: 251504659 BUSINESS ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 BUSINESS PHONE: 302 355-0650 MAIL ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 FORMER COMPANY: FORMER CONFORMED NAME: iBioPharma, Inc. DATE OF NAME CHANGE: 20080806 FORMER COMPANY: FORMER CONFORMED NAME: InB:Biotechnologies, Inc. DATE OF NAME CHANGE: 20071210 8-K 1 tm2531903d1_8k.htm FORM 8-K false 0001420720 0001420720 2025-11-20 2025-11-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (date of earliest event reported): November 20, 2025   iBio, Inc. (Exact name of registrant as specified in charter)   Delaware (State or other jurisdiction of incorporation)   001-35023 26-2797813 (Commission File Number) (IRS Employer Identification No.)   11750 Sorrento Valley Road , Suite 200 San Diego , California 92121 (Address of principal executive offices and zip code)   ( 979 ) 446-0027 (Registrant’s telephone number including area code)   N/A (Former Name and Former Address)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:     ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ¨ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)     ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value per share IBIO The Nasdaq Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company   ¨   If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ¨             Item 5.07. Submission of Matters to a Vote of Security Holders.   On November 20, 2025, iBio, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on four (4) proposals and cast their votes as described below. A total of 10,566,364 shares were represented in person or by proxy, which represented a quorum. The matters below are described in detail in the Company’s definitive proxy st

View on Read The Filing